Ignite Creation Date:
2025-12-25 @ 2:48 AM
Ignite Modification Date:
2025-12-31 @ 7:10 PM
Study NCT ID:
NCT05036733
Status:
COMPLETED
Last Update Posted:
2024-10-23
First Post:
2021-08-30
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24', 'submissionTracking': {'firstMcpInfo': {'postDateStruct': {'date': '2024-07-26', 'type': 'ACTUAL'}}}}, 'conditionBrowseModule': {'meshes': [{'id': 'D001249', 'term': 'Asthma'}], 'ancestors': [{'id': 'D001982', 'term': 'Bronchial Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012130', 'term': 'Respiratory Hypersensitivity'}, {'id': 'D006969', 'term': 'Hypersensitivity, Immediate'}, {'id': 'D006967', 'term': 'Hypersensitivity'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C582203', 'term': 'dupilumab'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'yvjhuang@med.umich.edu', 'phone': '734-936-5047', 'title': 'Yvonne J Huang MD', 'organization': 'University of Michigan'}, 'certainAgreement': {'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'timeFrame': '4 months', 'description': 'Non-serious adverse event information was not collected.', 'eventGroups': [{'id': 'EG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.', 'otherNumAtRisk': 0, 'deathsNumAtRisk': 15, 'otherNumAffected': 0, 'seriousNumAtRisk': 15, 'deathsNumAffected': 0, 'seriousNumAffected': 2}], 'seriousEvents': [{'term': 'Pneumonia-attributed acute respiratory failure', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Respiratory difficulty requiring hospitalization', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Acute myeloid leukemia diagnosis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 15, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Changes in Alpha-diversity of Respiratory Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.13', 'spread': '0.29', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': "α-diversity was calculated using the Shannon Diversity Index at the species level from induced sputum samples obtained at Baseline and after 1 month on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria.", 'unitOfMeasure': "Shannon's index", 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Changes in Alpha-diversity of Respiratory Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.14', 'spread': '0.30', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': "α-diversity was calculated using the Shannon Diversity Index at the species level from induced sputum samples obtained at baseline and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria.", 'unitOfMeasure': "Shannon's index", 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Changes in Alpha-diversity of Respiratory Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '-0.09', 'spread': '0.41', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '1 month, 4 months', 'description': "α-diversity was calculated using the Shannon Diversity Index at the species level from induced sputum samples obtained after 1 month and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria.", 'unitOfMeasure': "Shannon's index", 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Beta-diversity of Respiratory Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '.82', 'spread': '0.17', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from induced sputum samples obtained at baseline and after 1 month on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance, which is unitless, indicates a greater difference in diversity between the time points.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Beta-diversity of Respiratory Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.82', 'spread': '0.17', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from induced sputum samples obtained at baseline and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Beta-diversity of Respiratory Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.81', 'spread': '0.19', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '1 month, 4 months', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from induced sputum samples obtained after 1 month and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Relative Abundances of Microbiota Members', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'title': 'Streptococcus salivarius', 'categories': [{'measurements': [{'value': '-5.9', 'spread': '0.09', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus sanguinis', 'categories': [{'measurements': [{'value': '-2.4', 'spread': '0.04', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus parasanguinis', 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.05', 'groupId': 'OG000'}]}]}, {'title': 'Bifidobacterium longum', 'categories': [{'measurements': [{'value': '0.03', 'spread': '0.02', 'groupId': 'OG000'}]}]}, {'title': 'Tropheryma whipplei', 'categories': [{'measurements': [{'value': '0.2', 'spread': '0.04', 'groupId': 'OG000'}]}]}, {'title': 'Bifidobacterium dentium', 'categories': [{'measurements': [{'value': '0.3', 'spread': '0.01', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus gordonii', 'categories': [{'measurements': [{'value': '1.0', 'spread': '0.02', 'groupId': 'OG000'}]}]}, {'title': 'Parvimonas micra', 'categories': [{'measurements': [{'value': '1.6', 'spread': '0.04', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus anginosus', 'categories': [{'measurements': [{'value': '1.6', 'spread': '0.04', 'groupId': 'OG000'}]}]}, {'title': 'Rothia mucilaginosa', 'categories': [{'measurements': [{'value': '2.0', 'spread': '0.05', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': 'Relative abundance was calculated by finding the proportion of a classified species out of all bacterial classifications in an induced sputum sample. Relative abundance was calculated at baseline and after 1 month on dupilumab. The change in relative abundance of each species across all available samples was calculated by taking the difference between time points.', 'unitOfMeasure': 'percentage of bacterial classification', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Relative Abundances of Microbiota Members', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'title': 'Streptococcus salivarius', 'categories': [{'measurements': [{'value': '-0.2', 'spread': '0.07', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus sanguinis', 'categories': [{'measurements': [{'value': '1.1', 'spread': '0.02', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus parasanguinis', 'categories': [{'measurements': [{'value': '-2.6', 'spread': '0.1', 'groupId': 'OG000'}]}]}, {'title': 'Bifidobacterium longum', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '0.04', 'groupId': 'OG000'}]}]}, {'title': 'Tropheryma whipplei', 'categories': [{'measurements': [{'value': '2.4', 'spread': '0.03', 'groupId': 'OG000'}]}]}, {'title': 'Bifidobacterium dentium', 'categories': [{'measurements': [{'value': '-3.1', 'spread': '0.07', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus gordonii', 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.03', 'groupId': 'OG000'}]}]}, {'title': 'Parvimonas micra', 'categories': [{'measurements': [{'value': '0.6', 'spread': '0.04', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus anginosus', 'categories': [{'measurements': [{'value': '1.1', 'spread': '0.04', 'groupId': 'OG000'}]}]}, {'title': 'Rothia mucilaginosa', 'categories': [{'measurements': [{'value': '-4.0', 'spread': '0.09', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': 'Relative abundance was calculated by finding the proportion of a classified species out of all bacterial classifications in an induced sputum sample. Relative abundance was calculated at baseline and after 4 months on dupilumab. The change in relative abundance of each species across all available samples was calculated by taking the difference between time points.', 'unitOfMeasure': 'percent of bacterial classification', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Relative Abundances of Microbiota Members', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'title': 'Streptococcus salivarius', 'categories': [{'measurements': [{'value': '8.3', 'spread': '0.1', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus sanguinis', 'categories': [{'measurements': [{'value': '3.3', 'spread': '0.04', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus parasanguinis', 'categories': [{'measurements': [{'value': '-3.5', 'spread': '0.12', 'groupId': 'OG000'}]}]}, {'title': 'Bifidobacterium longum', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '0.02', 'groupId': 'OG000'}]}]}, {'title': 'Tropheryma whipplei', 'categories': [{'measurements': [{'value': '0.1', 'spread': '0', 'groupId': 'OG000'}]}]}, {'title': 'Bifidobacterium dentium', 'categories': [{'measurements': [{'value': '-4.5', 'spread': '0.08', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus gordonii', 'categories': [{'measurements': [{'value': '-1.6', 'spread': '0.04', 'groupId': 'OG000'}]}]}, {'title': 'Parvimonas micra', 'categories': [{'measurements': [{'value': '-1.2', 'spread': '0.02', 'groupId': 'OG000'}]}]}, {'title': 'Streptococcus anginosus', 'categories': [{'measurements': [{'value': '-0.5', 'spread': '0.01', 'groupId': 'OG000'}]}]}, {'title': 'Rothia mucilaginosa', 'categories': [{'measurements': [{'value': '-2.0', 'spread': '0.05', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '1 month, 4 months', 'description': 'Relative abundance was calculated by finding the proportion of a classified species out of all bacterial classifications in an induced sputum sample. Relative abundance was calculated after 1 month and after 4 months on dupilumab. The change in relative abundance of each species across all available samples was calculated by taking the difference between time points.', 'unitOfMeasure': 'percent of bacterial classification', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Respiratory Bacterial Burden', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '-16,117,353,849', 'spread': '19,829,305,914', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': 'Bacterial burden was estimated by scaling species relative abundances to a known cell count of Imtechella halotolerans (Zymo) that was spiked into an induced sputum sample before extraction for sequencing. Bacterial burden was calculated at baseline and after 1 month on dupilumab. The change in bacterial burden was calculated by aggregating all burden values per participant and taking the difference between time points.', 'unitOfMeasure': 'cells', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Respiratory Bacterial Burden', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '-25,294,991,477', 'spread': '44,588,805,244', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': 'Bacterial burden was estimated by scaling all species relative abundances to a known cell count of Imtechella halotolerans that was spiked into sputum samples before extraction for sequencing. Bacterial burden was calculated at baseline and after 4 months on dupilumab. The change in bacterial burden was calculated by aggregating all burden values per participant and taking the difference between time points.', 'unitOfMeasure': 'cells', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Respiratory Bacterial Burden', 'denoms': [{'units': 'Participants', 'counts': [{'value': '6', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '-9,927,388,331', 'spread': '44,588,805,244', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '1 month, 4 months', 'description': 'Bacterial Burden was estimated by scaling the species relative abundance to a known cell count of I. Halotolerans that was spiked into an induced sputum sample before extraction for sequencing. Bacterial burden was calculated at after 1 month and after 4 months on dupilumab. The change in bacterial burden was calculated by aggregating all burden values per participant and taking the difference between time points.', 'unitOfMeasure': 'cells', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Changes in Alpha-diversity of Stool Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.07', 'spread': '0.24', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': "α-diversity was calculated using the Shannon diversity index at the species level from stool samples obtained at baseline and after 1 month on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria.", 'unitOfMeasure': "Shannon's index", 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Changes in Alpha-diversity of Stool Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.04', 'spread': '0.29', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': "α-diversity was calculated using the Shannon diversity Index at the species level from stool samples obtained at baseline and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria.", 'unitOfMeasure': "Shannon's index", 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Changes in Alpha-diversity of Stool Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.42', 'spread': '0.67', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '1 month, 4 months', 'description': "α-diversity was calculated using the Shannon Diversity Index at the species level from stool samples. Shannon's Diversity Index values were obtained after 1 month and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria.", 'unitOfMeasure': "Shannon's index", 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Beta-diversity of Stool Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '4', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.72', 'spread': '0.14', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from stool samples. Samples were obtained baseline and after 1 month on dupilumab and the Bray-Curtis Distance calculated. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points..", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Beta-diversity of Stool Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.75', 'spread': '0.12', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from stool samples obtained at baseline and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'PRIMARY', 'title': 'Change in Beta-diversity of Stool Microbiota', 'denoms': [{'units': 'Participants', 'counts': [{'value': '2', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.71', 'spread': '0.14', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '1 month, 4 months', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from stool samples obtained after 1 month and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points.", 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'While 15 participants completed treatment, not all participants were able to provide biosamples. All data collected from available samples is provided here.'}, {'type': 'SECONDARY', 'title': 'Forced Expiratory Volume ( FEV1) / Forced Vital Capacity (FVC) Ratio', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'title': 'Visit 1', 'categories': [{'measurements': [{'value': '0.75', 'groupId': 'OG000', 'lowerLimit': '0.53', 'upperLimit': '0.91'}]}]}, {'title': 'Visit 2', 'categories': [{'measurements': [{'value': '0.78', 'groupId': 'OG000', 'lowerLimit': '0.51', 'upperLimit': '0.93'}]}]}, {'title': 'Visit 3', 'categories': [{'measurements': [{'value': '0.77', 'groupId': 'OG000', 'lowerLimit': '0.54', 'upperLimit': '0.92'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'Ratio of the volume of air exhaled in 1 sec (FEV1) divided by the total volume exhaled (FVC). FEV1/FVC \\< 0.70 (or less than lower limit of age-predicted normal) is clinically diagnostic of obstructive lung disease.', 'unitOfMeasure': 'ratio', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Forced Expiratory Volume (FEV1)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'title': 'Visit 1', 'categories': [{'measurements': [{'value': '85', 'groupId': 'OG000', 'lowerLimit': '54', 'upperLimit': '120'}]}]}, {'title': 'Visit 2', 'categories': [{'measurements': [{'value': '88', 'groupId': 'OG000', 'lowerLimit': '61', 'upperLimit': '137'}]}]}, {'title': 'Visit 3', 'categories': [{'measurements': [{'value': '89', 'groupId': 'OG000', 'lowerLimit': '57', 'upperLimit': '128'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'FEV1 measure reported as a percentage of predicted FEV1.', 'unitOfMeasure': 'percent of predicted volume', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change in Fractional Exhaled Nitric Oxide (FeNO)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'title': 'Visit 1', 'categories': [{'measurements': [{'value': '32', 'groupId': 'OG000', 'lowerLimit': '5', 'upperLimit': '127'}]}]}, {'title': 'Visit 2', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '6', 'upperLimit': '42'}]}]}, {'title': 'Visit 3', 'categories': [{'measurements': [{'value': '17', 'groupId': 'OG000', 'lowerLimit': '5', 'upperLimit': '45'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'Fractional exhaled nitric oxide is a clinical biomarker for type 2 airway inflammation. FeNO \\>25 is considered indicative of type 2 airway inflammation.', 'unitOfMeasure': 'parts per billion', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Asthma Control Test (ACT)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'title': 'Visit 1', 'categories': [{'measurements': [{'value': '15', 'groupId': 'OG000', 'lowerLimit': '7', 'upperLimit': '21'}]}]}, {'title': 'Visit 2', 'categories': [{'measurements': [{'value': '21', 'groupId': 'OG000', 'lowerLimit': '9', 'upperLimit': '25'}]}]}, {'title': 'Visit 3', 'categories': [{'measurements': [{'value': '21', 'groupId': 'OG000', 'lowerLimit': '11', 'upperLimit': '25'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'The Asthma Control Test is a clinically validated questionnaire that assesses level of asthma control based on a 4-week recall of symptoms and daily functioning captured in 5 items. Each item is scored on a 5-point scale, and the total score is the sum of the values for all 5 items (range 5-25). A score of 5 represents worst-controlled asthma and 25 represents best-controlled asthma. An ACT score \\>19 indicates well-controlled asthma; the minimal clinically important difference in score is 3.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Mini Asthma Quality of Life Questionnaire Score (mAQLQ)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'title': 'Visit 1', 'categories': [{'measurements': [{'value': '4.2', 'groupId': 'OG000', 'lowerLimit': '1.9', 'upperLimit': '7.0'}]}]}, {'title': 'Visit 2', 'categories': [{'measurements': [{'value': '5.2', 'groupId': 'OG000', 'lowerLimit': '2.7', 'upperLimit': '7.0'}]}]}, {'title': 'Visit 3', 'categories': [{'measurements': [{'value': '5.6', 'groupId': 'OG000', 'lowerLimit': '3.5', 'upperLimit': '6.9'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'The mini-Asthma Quality of Life Questionnaire (mAQLQ) consists of 15 questions covering 4 domains: symptoms (5 questions), activity limitations (4 questions), emotional function (3 questions), and environmental stimuli (3 questions). The recall time for the mAQLQ is 2 weeks and each item is scored on a 7-point scale. Total scores per participant are the average of the 15 items and range from 1-7, with higher scores indicative of better quality of life. The minimum clinically important difference is 0.5.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Sino-nasal Outcome Test (SNOT-22)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'title': 'Visit 1', 'categories': [{'measurements': [{'value': '44', 'groupId': 'OG000', 'lowerLimit': '3', 'upperLimit': '58'}]}]}, {'title': 'Visit 2', 'categories': [{'measurements': [{'value': '24', 'groupId': 'OG000', 'lowerLimit': '1', 'upperLimit': '63'}]}]}, {'title': 'Visit 3', 'categories': [{'measurements': [{'value': '21', 'groupId': 'OG000', 'lowerLimit': '5', 'upperLimit': '56'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'This is a 22 item questionnaire. Each item is rated as follows: 0=no problem, 1=very mild problem, 2=mild or slight problem, 3=moderate problem, 4=severe problem, 5=problem as bad as it can be. The score ranges between 0 and 110. A higher score means worse outcome.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Full Range', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Change in Prescribed Maintenance Corticosteroid Use (Inhaled or Oral), Between Baseline and 4 Months.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Baseline, 4 months', 'description': 'Count of participants whose maintenance corticosteroid prescription changed between baseline and 4 months.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Number of Asthma Exacerbations Requiring at Least 3 Days of Oral Corticosteroids', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'up to 4 months', 'description': 'Number of asthma exacerbations requiring at least 3 days of oral corticosteroids across the entire study population over the course of the study.', 'unitOfMeasure': 'count of exacerbations', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '15'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Dupilumab', 'description': 'Dupilumab: Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '59', 'spread': '18', 'groupId': 'BG000'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '7', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '8', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '15', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race/Ethnicity, Customized', 'classes': [{'title': 'White', 'categories': [{'measurements': [{'value': '14', 'groupId': 'BG000'}]}]}, {'title': 'Race other than White', 'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '15', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'FEV1:FVC', 'classes': [{'categories': [{'measurements': [{'value': '0.75', 'spread': '0.12', 'groupId': 'BG000'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'ratio', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Body-mass index', 'classes': [{'categories': [{'measurements': [{'value': '30.1', 'spread': '12.7', 'groupId': 'BG000'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': '(kg/m^2)', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Fractional exhaled nitric oxide (FeNO)', 'classes': [{'categories': [{'measurements': [{'value': '32', 'spread': '33', 'groupId': 'BG000'}]}]}], 'paramType': 'MEDIAN', 'unitOfMeasure': 'parts per billion', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Asthma Control Test (ACT) score', 'classes': [{'categories': [{'measurements': [{'value': '15', 'spread': '5', 'groupId': 'BG000'}]}]}], 'paramType': 'MEDIAN', 'description': 'The scores range from 5 (poor control of asthma) to 25 (complete control of asthma), with higher scores reflecting greater asthma control.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sino-nasal outcome test (SNOT-22) score', 'classes': [{'categories': [{'measurements': [{'value': '44', 'spread': '16', 'groupId': 'BG000'}]}]}], 'paramType': 'MEDIAN', 'description': 'The possible range of Total SNOT scores is between 0 to 110 for the SNOT-22.\n\nHigher scores indicate greater rhinosinusitis-related health burden.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'mini-Asthma Quality of Life Questionnaire (mAQLQ) score', 'classes': [{'categories': [{'measurements': [{'value': '4.2', 'spread': '1.2', 'groupId': 'BG000'}]}]}], 'paramType': 'MEDIAN', 'description': 'This is a patient self-administered questionnaire with 15 questions covering 4 domains: Symptoms (5 questions), Activity Limitations (4 questions), Emotional Function (3 questions), and Environmental Stimuli (3 questions). Scores range from 0-6 (lower is worse). The mini AQLQ score is calculated as the average of domain items. The minimum clinically important difference is 0.5.\n\nOverall score (average of 15 questions): add up responses to all questions, and divide by 15.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'alpha-diversity of respiratory (sputum) microbiota: Shannon index', 'classes': [{'categories': [{'measurements': [{'value': '3.08', 'spread': '0.36', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'description': 'α-diversity was calculated using the Shannon Diversity Index at the species level from induced sputum samples. A higher Shannon Diversity Index value indicates higher diversity.', 'unitOfMeasure': "Shannon's index", 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Relative abundances of respiratory (sputum) microbiota members', 'classes': [{'title': 'Streptococcus salivarius', 'categories': [{'measurements': [{'value': '17.8', 'spread': '14.5', 'groupId': 'BG000'}]}]}, {'title': 'Streptococcus sanguinis', 'categories': [{'measurements': [{'value': '2.2', 'spread': '1.2', 'groupId': 'BG000'}]}]}, {'title': 'Streptococcus parasanguinis', 'categories': [{'measurements': [{'value': '10.8', 'spread': '8.4', 'groupId': 'BG000'}]}]}, {'title': 'Bifidobacterium longum', 'categories': [{'measurements': [{'value': '0.81', 'spread': '1.5', 'groupId': 'BG000'}]}]}, {'title': 'Tropheryma whipplei', 'categories': [{'measurements': [{'value': '2.23', 'spread': '2.4', 'groupId': 'BG000'}]}]}, {'title': 'Bifidobacterium dentium', 'categories': [{'measurements': [{'value': '0.55', 'spread': '0.8', 'groupId': 'BG000'}]}]}, {'title': 'Streptococcus gordonii', 'categories': [{'measurements': [{'value': '2.9', 'spread': '3.7', 'groupId': 'BG000'}]}]}, {'title': 'Parvimonas micra', 'categories': [{'measurements': [{'value': '3.5', 'spread': '4.5', 'groupId': 'BG000'}]}]}, {'title': 'Streptococcus anginosus', 'categories': [{'measurements': [{'value': '3.5', 'spread': '8.7', 'groupId': 'BG000'}]}]}, {'title': 'Rothia mucilaginosa', 'categories': [{'measurements': [{'value': '7.2', 'spread': '5.6', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'description': 'Relative abundance was calculated by finding the proportion of a classified species out of all bacterial classifications in an induced sputum sample.', 'unitOfMeasure': 'percentages', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Respiratory bacterial burden (#bacterial cells, sputum)', 'classes': [{'categories': [{'measurements': [{'value': '4,622,000,000', 'spread': '6,443,000,000', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'bacterial cells', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'alpha-diversity of stool microbiota: Shannon index', 'classes': [{'categories': [{'measurements': [{'value': '3.20', 'spread': '0.31', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'description': 'α-diversity was calculated using the Shannon diversity Index at the species level from stool samples. A higher Shannon Diversity Index value indicates higher diversity.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Oral Corticosteroid Use', 'classes': [{'categories': [{'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'description': 'Number of participants using oral corticosteroids', 'unitOfMeasure': 'Participants'}, {'title': 'Blood eosinophils', 'classes': [{'categories': [{'measurements': [{'value': '200', 'spread': '200', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'cells/microliter', 'dispersionType': 'STANDARD_DEVIATION'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-09-08', 'size': 450417, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2024-06-21T12:11', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE4'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'BASIC_SCIENCE', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 15}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2022-02-22', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2024-10', 'completionDateStruct': {'date': '2023-06-29', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2024-10-02', 'studyFirstSubmitDate': '2021-08-30', 'resultsFirstSubmitDate': '2024-06-27', 'studyFirstSubmitQcDate': '2021-08-30', 'lastUpdatePostDateStruct': {'date': '2024-10-23', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2024-10-02', 'studyFirstPostDateStruct': {'date': '2021-09-08', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2024-10-23', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2023-06-29', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Changes in Alpha-diversity of Respiratory Microbiota', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': "α-diversity was calculated using the Shannon Diversity Index at the species level from induced sputum samples obtained at Baseline and after 1 month on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria."}, {'measure': 'Changes in Alpha-diversity of Respiratory Microbiota', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': "α-diversity was calculated using the Shannon Diversity Index at the species level from induced sputum samples obtained at baseline and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria."}, {'measure': 'Changes in Alpha-diversity of Respiratory Microbiota', 'timeFrame': '1 month, 4 months', 'description': "α-diversity was calculated using the Shannon Diversity Index at the species level from induced sputum samples obtained after 1 month and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria."}, {'measure': 'Change in Beta-diversity of Respiratory Microbiota', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from induced sputum samples obtained at baseline and after 1 month on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance, which is unitless, indicates a greater difference in diversity between the time points."}, {'measure': 'Change in Beta-diversity of Respiratory Microbiota', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from induced sputum samples obtained at baseline and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points."}, {'measure': 'Change in Beta-diversity of Respiratory Microbiota', 'timeFrame': '1 month, 4 months', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from induced sputum samples obtained after 1 month and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points."}, {'measure': 'Change in Relative Abundances of Microbiota Members', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': 'Relative abundance was calculated by finding the proportion of a classified species out of all bacterial classifications in an induced sputum sample. Relative abundance was calculated at baseline and after 1 month on dupilumab. The change in relative abundance of each species across all available samples was calculated by taking the difference between time points.'}, {'measure': 'Change in Relative Abundances of Microbiota Members', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': 'Relative abundance was calculated by finding the proportion of a classified species out of all bacterial classifications in an induced sputum sample. Relative abundance was calculated at baseline and after 4 months on dupilumab. The change in relative abundance of each species across all available samples was calculated by taking the difference between time points.'}, {'measure': 'Change in Relative Abundances of Microbiota Members', 'timeFrame': '1 month, 4 months', 'description': 'Relative abundance was calculated by finding the proportion of a classified species out of all bacterial classifications in an induced sputum sample. Relative abundance was calculated after 1 month and after 4 months on dupilumab. The change in relative abundance of each species across all available samples was calculated by taking the difference between time points.'}, {'measure': 'Change in Respiratory Bacterial Burden', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': 'Bacterial burden was estimated by scaling species relative abundances to a known cell count of Imtechella halotolerans (Zymo) that was spiked into an induced sputum sample before extraction for sequencing. Bacterial burden was calculated at baseline and after 1 month on dupilumab. The change in bacterial burden was calculated by aggregating all burden values per participant and taking the difference between time points.'}, {'measure': 'Change in Respiratory Bacterial Burden', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': 'Bacterial burden was estimated by scaling all species relative abundances to a known cell count of Imtechella halotolerans that was spiked into sputum samples before extraction for sequencing. Bacterial burden was calculated at baseline and after 4 months on dupilumab. The change in bacterial burden was calculated by aggregating all burden values per participant and taking the difference between time points.'}, {'measure': 'Change in Respiratory Bacterial Burden', 'timeFrame': '1 month, 4 months', 'description': 'Bacterial Burden was estimated by scaling the species relative abundance to a known cell count of I. Halotolerans that was spiked into an induced sputum sample before extraction for sequencing. Bacterial burden was calculated at after 1 month and after 4 months on dupilumab. The change in bacterial burden was calculated by aggregating all burden values per participant and taking the difference between time points.'}, {'measure': 'Changes in Alpha-diversity of Stool Microbiota', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': "α-diversity was calculated using the Shannon diversity index at the species level from stool samples obtained at baseline and after 1 month on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria."}, {'measure': 'Changes in Alpha-diversity of Stool Microbiota', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': "α-diversity was calculated using the Shannon diversity Index at the species level from stool samples obtained at baseline and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria."}, {'measure': 'Changes in Alpha-diversity of Stool Microbiota', 'timeFrame': '1 month, 4 months', 'description': "α-diversity was calculated using the Shannon Diversity Index at the species level from stool samples. Shannon's Diversity Index values were obtained after 1 month and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' calculated diversity and then finding the difference between time points. A higher Shannon Diversity Index value indicates higher diversity. A value of zero indicates the presence of only one kind of species of bacteria."}, {'measure': 'Change in Beta-diversity of Stool Microbiota', 'timeFrame': 'Baseline (before dupilumab), 1 month', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from stool samples. Samples were obtained baseline and after 1 month on dupilumab and the Bray-Curtis Distance calculated. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points.."}, {'measure': 'Change in Beta-diversity of Stool Microbiota', 'timeFrame': 'Baseline (before dupilumab), 4 month', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from stool samples obtained at baseline and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points."}, {'measure': 'Change in Beta-diversity of Stool Microbiota', 'timeFrame': '1 month, 4 months', 'description': "Beta-diversity was calculated using the Bray-Curtis Distance at the species level from stool samples obtained after 1 month and after 4 months on dupilumab. The change in diversity was calculated by aggregating all participants' distance between time points. Bray-Curtis dissimilarity ranges from 0 to 1. A higher Bray-Curtis Distance indicates a greater difference in diversity between time points."}], 'secondaryOutcomes': [{'measure': 'Forced Expiratory Volume ( FEV1) / Forced Vital Capacity (FVC) Ratio', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'Ratio of the volume of air exhaled in 1 sec (FEV1) divided by the total volume exhaled (FVC). FEV1/FVC \\< 0.70 (or less than lower limit of age-predicted normal) is clinically diagnostic of obstructive lung disease.'}, {'measure': 'Forced Expiratory Volume (FEV1)', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'FEV1 measure reported as a percentage of predicted FEV1.'}, {'measure': 'Change in Fractional Exhaled Nitric Oxide (FeNO)', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'Fractional exhaled nitric oxide is a clinical biomarker for type 2 airway inflammation. FeNO \\>25 is considered indicative of type 2 airway inflammation.'}, {'measure': 'Asthma Control Test (ACT)', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'The Asthma Control Test is a clinically validated questionnaire that assesses level of asthma control based on a 4-week recall of symptoms and daily functioning captured in 5 items. Each item is scored on a 5-point scale, and the total score is the sum of the values for all 5 items (range 5-25). A score of 5 represents worst-controlled asthma and 25 represents best-controlled asthma. An ACT score \\>19 indicates well-controlled asthma; the minimal clinically important difference in score is 3.'}, {'measure': 'Mini Asthma Quality of Life Questionnaire Score (mAQLQ)', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'The mini-Asthma Quality of Life Questionnaire (mAQLQ) consists of 15 questions covering 4 domains: symptoms (5 questions), activity limitations (4 questions), emotional function (3 questions), and environmental stimuli (3 questions). The recall time for the mAQLQ is 2 weeks and each item is scored on a 7-point scale. Total scores per participant are the average of the 15 items and range from 1-7, with higher scores indicative of better quality of life. The minimum clinically important difference is 0.5.'}, {'measure': 'Sino-nasal Outcome Test (SNOT-22)', 'timeFrame': 'Baseline, 1 month, 4 months', 'description': 'This is a 22 item questionnaire. Each item is rated as follows: 0=no problem, 1=very mild problem, 2=mild or slight problem, 3=moderate problem, 4=severe problem, 5=problem as bad as it can be. The score ranges between 0 and 110. A higher score means worse outcome.'}, {'measure': 'Change in Prescribed Maintenance Corticosteroid Use (Inhaled or Oral), Between Baseline and 4 Months.', 'timeFrame': 'Baseline, 4 months', 'description': 'Count of participants whose maintenance corticosteroid prescription changed between baseline and 4 months.'}, {'measure': 'Number of Asthma Exacerbations Requiring at Least 3 Days of Oral Corticosteroids', 'timeFrame': 'up to 4 months', 'description': 'Number of asthma exacerbations requiring at least 3 days of oral corticosteroids across the entire study population over the course of the study.'}]}, 'oversightModule': {'isUsExport': False, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Inhaled corticosteroids', 'Dupilumab'], 'conditions': ['Asthma']}, 'descriptionModule': {'briefSummary': 'The overall goal of this study is to understand biological responses related to dupilumab treatment among severe asthma patients.\n\nNot all asthma is the same, and characteristics of asthma vary from person to person. The study will investigate whether the study drug can help to improve the health of participants lungs, boost immune response, as well as improve quality of life.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Physician-diagnosed/managed severe asthma patients that are clinically eligible for dupilumab\n* Current treatment with a medium-to-high-dose inhaled glucocorticoid (fluticasone propionate at a total daily dose of greater or equal (≥) 440 μg or equipotent equivalent) plus up to at least one additional controller (e.g., a long-acting β2-agonist or leukotriene receptor antagonist)\n* Eosinophilic asthma phenotype (blood eosinophil level \\>300) or asthma requiring daily oral corticosteroids\n* Asthma that is uncontrolled, as defined by a score on the Asthma Control Test of 19 or lower, or a worsening of asthma in the past year that led to an asthma hospitalization, Emergency Department visit, or 3 days of oral corticosteroids\n* Severity of asthma that, in the opinion of the subject's asthma care specialist, requires dupilumab for control\n* For women of childbearing age: agree to use birth control or remain abstinent during the duration of the study.\n\nExclusion Criteria:\n\n* Patients with diagnosis of other chronic lung diseases (e.g. Chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis, Churg-Strauss syndrome, Allergic bronchopulmonary aspergillosis, etc.)\n* Current smoker or reported smoking within 1 month of the screening visit (tobacco or any inhaled recreational product)\n* Greater than 10 total pack-year of cigarette smoking history\n* Treatment with oral corticosteroids for an asthma exacerbation 1 month prior to screening or during the screening period\n* Use of any biologic therapy for asthma within the past 3 months\n* Respiratory or Gastrointestinal illness within 1 month prior to screening or during the screening period\n* Treatment with antibiotics for acute infections within six weeks prior to screening or during the screening period.\n* Pregnancy at enrollment or during the study\n* Known hypersensitivity to dupilumab or its excipients"}, 'identificationModule': {'nctId': 'NCT05036733', 'briefTitle': 'Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma', 'organization': {'class': 'OTHER', 'fullName': 'University of Michigan'}, 'officialTitle': 'Effects of IL-4R-alpha Inhibition (Dupixent) Inhibition On The Respiratory Microbiome And Immunologic Correlates In Patients With Severe Asthma', 'orgStudyIdInfo': {'id': 'HUM00196809'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Dupilumab', 'interventionNames': ['Drug: Dupilumab']}], 'interventions': [{'name': 'Dupilumab', 'type': 'DRUG', 'otherNames': ['Dupixent'], 'description': 'Participants will receive 8 doses of Dupilumab. The initial loading dose (visit 1) of 600 milligrams (two 300 milligram injections) will be given subcutaneously (SQ). Then the participants will receive 300 milligrams SQ every other week (q 2 weeks) either at a study visit or self-administered at home between visits.\n\nAdditionally, participants will complete questionnaires, have specimens collected, as well as perform breathing procedures at various timepoints.', 'armGroupLabels': ['Dupilumab']}]}, 'contactsLocationsModule': {'locations': [{'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}], 'overallOfficials': [{'name': 'Yvonne Huang, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'University of Michigan'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'University of Michigan', 'class': 'OTHER'}, 'collaborators': [{'name': 'Regeneron Pharmaceuticals', 'class': 'INDUSTRY'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Associate Professor of Internal Medicine and Microbiology/Immunology', 'investigatorFullName': 'Yvonne J Huang', 'investigatorAffiliation': 'University of Michigan'}}}}